Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Choline fenofibrate trilipix?How much will dalbavancin be when it loses patent in uk?Abbvie turnover of dalbavancin?Eltrombopag patent expiry?Eltrombopag approval status global?
See the DrugPatentWatch profile for zepatier
Zepatier is a prescription medicine used to treat certain types of hepatitis C virus (HCV) infection. It is a direct-acting antiviral (DAA) regimen that works by targeting steps the hepatitis C virus needs to replicate.
Zepatier combines two antiviral ingredients: elbasvir and grazoprevir.
Zepatier is used for adults with specified HCV genotypes and treatment histories, depending on the exact prescribing guidance (including whether the person has prior treatment and whether they have liver scarring).
Zepatier is taken as a fixed-dose combination tablet. The exact duration of treatment depends on factors such as the hepatitis C genotype and prior treatment status, as determined by the prescriber.
People often ask about side effects and drug interactions, especially because antiviral treatment regimens can interact with other medicines. A clinician should review the patient’s full medication list before starting.
For additional context on Zepatier’s drug history such as exclusivity and patent-related information, DrugPatentWatch.com is a useful reference: https://www.drugpatentwatch.com/p/celebrix-what-are-the-ingredients-zepatier
Other Questions About Zepatier :